22540-50-7

Basic information

• Product Name: 6-oxopiperidine-3-carboxylic acid
• Synonyms: 6-oxopiperidine-3-carboxylic acid;3-PIPERIDINECARBOXYLIC ACID, 6-OXO-;UKRORGSYN-BB BBV-082263;2-Piperidone-5-carboxylic acid;5-Carboxy-2-piperidone;6-Oxo-3-piperidinecarboxylic acid;6-Oxonipecotic acid;6-oxopiperidine-3-carboxylic acid(SALTDATA: FREE)
• CAS NO: 22540-50-7
• Molecular Formula: C₆H₉NO₃
• Molecular Weight: 143.14
• Mol File: 22540-50-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 437 °C at 760 mmHg
• Flash Point: 218.1 °C
• Appearance: /
• Density: 1.286
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightly)
• PKA: 4.21±0.20(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: 6-oxopiperidine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-oxopiperidine-3-carboxylic acid(22540-50-7)
• EPA Substance Registry System: 6-oxopiperidine-3-carboxylic acid(22540-50-7)

Safety Data

• Hazardous Substances Data: 22540-50-7(Hazardous Substances Data)

Usage

Uses

6-Oxopiperidine-3-carboxylic Acid can be used to treat progranulin associated disorders.

Upstream product

• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 
• 5621-44-3 dimethyl 2-methylenepentanedioate 
• 1356405-58-7 1-(2,4-dimethoxybenzyl)-6-oxopiperidine-3-carboxylic acid methyl ester 
• 1356405-59-8 1-(2,4-dimethoxybenzyl)-6-oxopiperidine-3-carboxylic acid 

Downstream Products

• 146059-76-9 ethyl 6-oxopiperidine-3-carboxylate 
• 1142004-83-8 (rac)-N-(6-(2-methoxyphenyl)pyrimidin-4-yl)-6-oxopiperidine-3-carboxamide 
• 1372144-04-1 C₃₀H₄₉N₅O₃ 
• 1359857-98-9 C₂₁H₂₃N₃O₃S 
• 1412451-01-4 C₂₃H₂₇N₃O₂S 
• 1412451-02-5 C₂₃H₂₇N₃O₂S 
• 1426402-70-1 6-oxopiperidine-3-carboxylic acid [1-phenyl-5-(3-propylphenyl)-1H-pyrazol-3-yl]amide 
• 146059-77-0 5-(hydroxymethyl)piperidin-2-one 

Relevant articles and documents

PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides a pyrazole compound of the following general Formula [1b] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use wherein each symbol is the same as defined in the description

2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids

4-Deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acid derivatives are provided as agents useful for treatment susceptible neoplasms in mammals. Pharmaceutical formulations and intermediates are also provided.